Divestiture News & Analysis
2 articles
Market Mood
Edwards Lifesciences Trading at $83.92 with Strong Growth Prospects
As of March 16, 2026, Edwards Lifesciences Corporation's share price was $83.92, with a trailing P/E of 46.17 and a forward P/E of 28.49. The company completed a $4.2 billion divestiture of its Critical Care business, which affected approximately 20% of its 2023 EBITDA base. However, the Transcatheter Mitral and Tricuspid Therapies segment is growing over 50% year-over-year, while the Transcatheter Aortic Valve Replacement franchise generates over $4.5 billion in annual revenue with 12%+ growth. Edwards Lifesciences has a strong balance sheet, holding $3.8 billion in cash and is trading at a valuation of approximately 21.3x EV/NTM EBITDA, below its historical average of 26x.
Read More
PTC Completes $523M Sale of Kepware & ThingWorx, Raises FY2026 Cash Flow
PTC has completed the sale of its Kepware and ThingWorx businesses for $523 million, resulting in net after-tax proceeds of $375 million and a gain of $464 million. The company raised its fiscal 2026 free cash flow guidance to $850 million, despite an anticipated cash flow headwind of approximately $70 million in FY27 due to a transition services agreement with TPG. PTC plans to allocate $1.125 to $1.225 billion for share repurchases. This divestiture allows PTC to focus more on its intelligent product lifecycle vision.
Read More